These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 18554353)

  • 1. A case of heroin overdose reversed by sublingually administered buprenorphine/naloxone (Suboxone).
    Welsh C; Sherman SG; Tobin KE
    Addiction; 2008 Jul; 103(7):1226-8. PubMed ID: 18554353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
    Alho H; Sinclair D; Vuori E; Holopainen A
    Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment.
    Mégarbane B; Buisine A; Jacobs F; Résière D; Chevillard L; Vicaut E; Baud FJ
    J Subst Abuse Treat; 2010 Jun; 38(4):403-7. PubMed ID: 20189341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of buprenorphine to reverse opioid overdose deserves further evaluation.
    Welsh C
    Addiction; 2008 Dec; 103(12):2066-7. PubMed ID: 19469753
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose.
    Yokell MA; Zaller ND; Green TC; McKenzie M; Rich JD
    J Opioid Manag; 2012; 8(1):63-6. PubMed ID: 22479887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of sublingual buprenorphine-naloxone for reversing heroin overdose: a high-risk strategy that should not be recommended.
    Nielsen S; Lintzeris N
    Addiction; 2008 Dec; 103(12):2065-6. PubMed ID: 19469751
    [No Abstract]   [Full Text] [Related]  

  • 7. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence.
    Bell J; Byron G; Gibson A; Morris A
    Drug Alcohol Rev; 2004 Sep; 23(3):311-7. PubMed ID: 15370011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose.
    Kerr D; Kelly AM; Dietze P; Jolley D; Barger B
    Addiction; 2009 Dec; 104(12):2067-74. PubMed ID: 19922572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: a prospective, multicenter study.
    Daulouède JP; Caer Y; Galland P; Villeger P; Brunelle E; Bachellier J; Piquet JM; Harbonnier J; Leglise Y; Courty P
    J Subst Abuse Treat; 2010 Jan; 38(1):83-9. PubMed ID: 19800758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent opioid toxicity after pre-hospital care of presumed heroin overdose patients.
    Boyd JJ; Kuisma MJ; Alaspää AO; Vuori E; Repo JV; Randell TT
    Acta Anaesthesiol Scand; 2006 Nov; 50(10):1266-70. PubMed ID: 17067327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia.
    Vicknasingam B; Mazlan M; Schottenfeld RS; Chawarski MC
    Drug Alcohol Depend; 2010 Sep; 111(1-2):44-9. PubMed ID: 20478668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose.
    Wampler DA; Molina DK; McManus J; Laws P; Manifold CA
    Prehosp Emerg Care; 2011; 15(3):320-4. PubMed ID: 21612385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The distribution of naloxone to heroin users.
    Darke S; Hall W
    Addiction; 1997 Sep; 92(9):1195-9. PubMed ID: 9374020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared.
    McKeganey N; Russell C; Cockayne L
    J Subst Abuse Treat; 2013 Jan; 44(1):97-102. PubMed ID: 22703715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infrequent opioid overdose risk reduction behaviours among young adult heroin users in cities with wide coverage of HIV prevention programmes.
    Neira-León M; Barrio G; Bravo MJ; Brugal MT; de la Fuente L; Domingo-Salvany A; Pulido J; Santos S;
    Int J Drug Policy; 2011 Jan; 22(1):16-25. PubMed ID: 20800462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with naloxone administration in an opioid dependent sample.
    Kenney SR; Anderson BJ; Bailey GL; Stein MD
    J Subst Abuse Treat; 2018 Jan; 84():17-20. PubMed ID: 29195589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.
    Comer SD; Sullivan MA; Vosburg SK; Manubay J; Amass L; Cooper ZD; Saccone P; Kleber HD
    Addiction; 2010 Apr; 105(4):709-18. PubMed ID: 20403021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription naloxone: a novel approach to heroin overdose prevention.
    Sporer KA; Kral AH
    Ann Emerg Med; 2007 Feb; 49(2):172-7. PubMed ID: 17141138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.